Abstract

Research Article

Prognostic factors for chronic kidney disease and end-stage renal disease in patients with lupus nephritis: A retrospective cohort study

Fernanda Nogueira Holanda Ferreira Braga*, Marta Maria das Chagas Medeiros, Antônio Brazil Viana Jr., Levi Coelho Maia Barros, Marcelo Ximenes Pontes, Matheus Eugênio de Sousa Lima, Allyson Wosley de Sousa Lima and Paula Frassinetti Castelo Branco Camurça Fernandes

Published: 27 April, 2021 | Volume 5 - Issue 1 | Pages: 034-041

Background: Lupus Nephritis (LN) occurs in approximately half of all patients with Systemic Lupus Erythematosus (SLE) and it is the most common cause of morbidity and mortality in patients with SLE. Factors associated with poor renal outcome vary among studies, and researches coming from Brazil are scarce.

Objectives: To identify the prognostic factors associated to the development of Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) in LN patients followed in a tertiary hospital.

Design and Settings: We conducted a retrospective cohort study set in a tertiary hospital in Fortaleza, Ceará, Brazil. Methods: We compiled a total of 214 LN patients diagnosed between 1983 and 2015. Data was collected from medical records and further analyzed using logistic regression.

Results: LN prevalence was 53.9%. The cohort had a mean follow-up of 11.2 years (SD ± 7.2 years). At the end of follow-up, 93 of 197 patients (47.2%) had CKD, and 49 of 191 (25.6%) were on regular dialysis. The main factors associated for developing CKD after logistic regression analysis were the following predictors: hypertension (HR 2.80; 95% CI 1.30-6.01; p = 0.008), time between diagnosis of SLE and diagnosis of LN (HR 0.98; 95% CI 0.97-0.99; p = 0.009) and discontinuation of medications (HR 2.41; 95% CI 1.08-5.37; p = 0.03).

Conclusion: Hypertension, discontinuation of medications, and time between diagnosis of SLE and diagnosis of LN are independent variables associated with the development of CKD and ESDR in our study. 

Read Full Article HTML DOI: 10.29328/journal.jcn.1001071 Cite this Article Read Full Article PDF

Keywords:

Lupus; Lupus nephritis; Prognostic features; Epidemiology; Mesh terms: Nephritis, Lupus; End Stage Renal Disease; Chronic Kidney Disease; Risk Factor

References

  1. Rovin BH, Stillman I. Chapter 42: Kidney. In: Lahita R, editor. Systemic Lupus Erythematosus. 5th ed. San Diego: Academic Press; 2011. 769-814.
  2. Hanly JG, O`Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016; 55: 252-262. PubMed: https://pubmed.ncbi.nlm.nih.gov/26342222/
  3. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, et al. European Working Party on Systemic Lupus Erythematosus: morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003; 82: 299-308. PubMed: https://pubmed.ncbi.nlm.nih.gov/14530779/
  4. Font J, Cervera R, Ramos-Casals, García-Carrasco M, Sents J, et al. Clusters of clinical and immunological features in systemic lupus erythematosus: analysis of 600 patients from a single Center. Sem Arthritis Rheum. 2004; 33: 217-230. PubMed: https://pubmed.ncbi.nlm.nih.gov/14978660/
  5. Pons-Estel B, Catoggio L, Cardiel M, Soriano ER, Gentiletti S, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus. Medicine. 2004; 83: 1-17. PubMed: https://pubmed.ncbi.nlm.nih.gov/14747764/
  6. Gasparotto M, Gatto M, Binda V, Doria A, Moroni G, et al. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford) 2020 Dec 5; 59(Suppl5): v39-v51. PubMed: https://pubmed.ncbi.nlm.nih.gov/33280015/
  7. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011; 365: 2110-2121. PubMed: https://pubmed.ncbi.nlm.nih.gov/22129255/
  8. Wang H, Ren Y, Chang J, Gu L, Sun LY. A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol. 2018; 33: 17-25. PubMed: https://pubmed.ncbi.nlm.nih.gov/29900975/
  9. McCullough PA, Verril TA. Cardiorenal interation: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med. 2010; 122: 25-34. PubMed: https://pubmed.ncbi.nlm.nih.gov/20203453/
  10. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010; 268: 456-467. PubMed: https://pubmed.ncbi.nlm.nih.gov/20809922/
  11. Sule S, Fivush B, Neu A, Furth S. Increased hospitalizations and death in patients with ESRD secondary to lupus. Lupus. 2012; 21: 1208-1203. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906535/
  12. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006; 33: 1563-1569. PubMed: https://pubmed.ncbi.nlm.nih.gov/16881113/
  13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271-1277. PubMed: https://pubmed.ncbi.nlm.nih.gov/7138600/
  14. Weening JJ, D’Agati VD, Schwartz MM, et al. on behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the classification of lupus nephritis. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. 2004; 15: 241-250.
  15. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes. Kidney Int. 2005; 67: 2089-2100. PubMed: https://pubmed.ncbi.nlm.nih.gov/15882252/
  16. Durahim HA, Ghamdi GA, Seraya AA, Alkhiari R, Sayyari AA. Predictors of mortality and end stage renal disease in Saudi patients with lupus nephritis. Lupus. 2011; 20: 1329-1335. PubMed: https://pubmed.ncbi.nlm.nih.gov/21813588/
  17. Kammoun K, Jarraya F, Bouhamed L, Kharrat M, Makni S, et al. Poor prognostic factors of lupus nephritis. Saudi J Kidney Dis Transpla. 2011; 2: 727-732. PubMed: https://pubmed.ncbi.nlm.nih.gov/21743218/
  18. Yang J, Liang D, Zhang H, Liu Z, Le W, et al. Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. Lupus. 2015; 24: 1468-1478. PubMed: https://pubmed.ncbi.nlm.nih.gov/26139236/
  19. Nossent J, Raymond W, Kang A, Wong D, Ognjenovic M, et al. The current role for clinical and renal histological findings as predictor for outcome in Australian patients with lupus nephritis. Lupus. 2018; 27: 1838-1846. PubMed: https://pubmed.ncbi.nlm.nih.gov/30092734/
  20. Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology 2010; 15: 482-490. PubMed: https://pubmed.ncbi.nlm.nih.gov/20609103/
  21. Pakchotanon R, Gladman DD, Su J, Urowitz MB. Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis. Lupus. 2017; 27: 468-474. PubMed: https://pubmed.ncbi.nlm.nih.gov/28857717/
  22. Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med. 2000; 160: 3136-3140. PubMed: https://pubmed.ncbi.nlm.nih.gov/11074743/
  23. Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol. 2009; 36: 63-67. PubMed: https://pubmed.ncbi.nlm.nih.gov/19004042/
  24. Ishimori ML, Gudsoorkar V, Venturupalli SR, Weisman MH. Disparities in renal replacement in lupus nephritis: current practice and future implications. Arthritis Care Rea. 2011; 63: 1639-1641. PubMed: https://pubmed.ncbi.nlm.nih.gov/22127964/ +
  25. Hiraki L, Lu B, Alexander S, Alarcón GS, Solomon DH, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum. 2011; 63: 1988-1997. PubMed: https://pubmed.ncbi.nlm.nih.gov/21445963/
  26. Ward MM, Studenski S. Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations. J Rheumatol. 1990; 17: 220-224. PubMed: https://pubmed.ncbi.nlm.nih.gov/2319521/
  27. Resende A, Titan S, Barros R, et al. Worse renal outcome of lupus nephritis in male patients: a case-control study. Lupus. 2011; 20: 561-567. PubMed: https://pubmed.ncbi.nlm.nih.gov/21415256/
  28. Renau AI, Isenberg DA. Male versus female lupus: a comparison of ethnicity, clinical features, serology and outcome over a 30 year period. Lupus. 2012; 21: 1041-1048. PubMed: https://pubmed.ncbi.nlm.nih.gov/22505605/
  29. Urrestarazú A, Otatti G, Silvariño R, Garau M, Coitiño R, et al. Lupus nephritis in males: clinical features, course, and prognostic factors for end-stage renal disease. Kidney Int Rep. 2017; 2: 905-912. PubMed: https://pubmed.ncbi.nlm.nih.gov/29270496/
  30. Fiehn C. Early diagnosis and treatment in lupus nephritis: how we can influence the risk for terminal renal failure. J Rheumatol. 2006; 33: 1464-1466. PubMed: https://pubmed.ncbi.nlm.nih.gov/16881102/
  31. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis. 2003; 62: 435-439. PubMed: https://pubmed.ncbi.nlm.nih.gov/12695156/
  32. Costenbader K, Desai A, Alarcon G, Hiraki LT, Shaykevich T, et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011; 63: 1681-1688. PubMed: https://pubmed.ncbi.nlm.nih.gov/21445962/
  33. Ward MM. Access care incidence end-stage renal disease due systemic lupus erythematosus. J Rheumatol. 2010; 37: 1158-1163. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952403/
  34. Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013; 346: 319-323. PubMed: https://pubmed.ncbi.nlm.nih.gov/23370533/
  35. Moon SJ, Kwok SK, Ju JH, Park KS, Park SH, et al. Predictors of chronic kidney disease in Korean patients with lupus nephritis. J Rheumatol. 2011; 38: 2588-2597. PubMed: https://pubmed.ncbi.nlm.nih.gov/21965650/
  36. Sui M, Ye X, Ma J, Yu C, Zhao S, et al. Epidemiology and risk factors for chronic kidney disease in Chinese patients with biopsy-proven lupus nephritis. Intern Med J. 2015; 45: 1167-1172. PubMed: https://pubmed.ncbi.nlm.nih.gov/26109241/
  37. Franco C, Yoo W, Franco D, Xu Z. Predictors of end stage renal disease in African Americans with lupus nephritis. Bull NYU Hosp Jt Dis. 2010; 68: 251-256. PubMed: https://pubmed.ncbi.nlm.nih.gov/21162701/
  38. Vozmediano C, Rivera F, López-Gómez JM, Hernández D. Risk factors for renal failure in patients with lúpus nephritis: data from the Spanish Registry of Glomerulonephritis. Nephron Extra. 2012; 2: 269-277. PubMed: https://pubmed.ncbi.nlm.nih.gov/23139689/
  39. Momtaz M, Fayed A, Wadie M, Gamal SM, Ghoniem SA, et al. Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. Lupus. 2017; 26: 1564-1570. PubMed: https://pubmed.ncbi.nlm.nih.gov/28625079/
  40. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology. 2011; 50: 1424-1430. PubMed: https://pubmed.ncbi.nlm.nih.gov/21415024/
  41. Uribe AG, Alarcón GS, Sanchez ML, McGwin G, Jr., Sandoval R, et al. Lumina Study Group. Systemic lupus erythematosus in three ethnic groups. XVIII. Factors predictive of poor compliance with study visits. Arthritis Rheum. 2004; 51: 258-263. PubMed: https://pubmed.ncbi.nlm.nih.gov/15077269/
  42. Rivera F, Anaya S. Lupus nephritis flare in young patients: relapse or nonadherence to treatment? Int J Nephrol Dis. 2014; 7: 117-121. PubMed: https://pubmed.ncbi.nlm.nih.gov/24729723/
  43. Bertsias GK, Teknidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and pediatric lupus nephritis. Ann Rheum Dis. 2012; 71: 1771-1882.
  44. Ichinose K, Kitamura M, Sato S, Eguchi M, Okamoto M, et al. Complete renal remission at 12 months after induction therapy is associated with renal relapse-free rate in lupus nephritis: a single-center, retrospective cohort study. Lupus. 2019; 28: 501-509. PubMed: https://pubmed.ncbi.nlm.nih.gov/30755146/
  45. Korbert SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, et al. for the Lupus Nephritis Collaborating Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis. 2000; 35: 904-914. PubMed: https://pubmed.ncbi.nlm.nih.gov/10793026/
  46. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ. Collaborative Study Group. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008; 3: 46-53. PubMed: https://pubmed.ncbi.nlm.nih.gov/18003764/
  47. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000; 57: 258-264. PubMed: https://pubmed.ncbi.nlm.nih.gov/10620207/
  48. Sprangers B, Monahan M, Appel GB. Diagnosis and treatment of lupus nephritis flares – an update. Nat Rev Nephrol. 2012; 8: 709-717. PubMed: https://pubmed.ncbi.nlm.nih.gov/23147758/
  49. Tamirou F, Lauwerys BR, Dall`Era M, Mackay M, Rovin B, et al. A proteinuria cut-off level of 0.7g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis. Data from the MAINTAIN Nephritis Trial. Lupus Sci Med. 2015; 2. PubMed: https://pubmed.ncbi.nlm.nih.gov/26629352/
  50. Dall´Era m, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lúpus nephritis Trial: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015; 67: 1305-1313.
  51. Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, et al. Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis Rheumatol. 2019; 71: 411-419. PubMed: https://pubmed.ncbi.nlm.nih.gov/30225865/
  52. Ahn SS, Yoo J, Jung SM, et al. Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis. BMC Nephrol. 2020; 21: 258.
  53. Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, et al. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) reccomendations. RMD Open. 2020; 6: e001263. PubMed: https://pubmed.ncbi.nlm.nih.gov/32699043/
  54. de Castro WP, Morales JV, Wagner MB, Graudenz M, Edelweiss MI, et al. Hypertension and Afro-descendent ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide? Lupus. 2007; 16: 724-730. PubMed: https://pubmed.ncbi.nlm.nih.gov/17728366/
  55. Ginzler EM, Felson DT, Anthony JM, Anderson JJ. Hypertension increases the risk of renal deterioration in systemic lupus erythematosus. J Rheumatol. 1993; 20: 1694-1700.

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?